Vizgen to Merge With Ultivue, Announces Series D Financing

NEW YORK—Vizgen, a high-resolution spatial transcriptomics startup, and Ultivue, a multiplex proteomic spatial tissue profiling firm, announced on Wednesday that they will merge.

Rob Carson, formerly CEO of Ultivue, will become the CEO and president of the newly combined Vizgen. Terry Lo, who served as Vizgen’s CEO starting in 2020 will continue to serve as a member of the board of directors.

Vizgen also said it has completed its Series D equity financing round for an undisclosed amount. Arch Venture Partners, Northpond Ventures, and Tao Capital Partners participated in the round.

“This merger represents a pivotal moment in the evolution of spatial multiomics. By bringing together Vizgen’s expertise in single-cell spatial genomics and Ultivue’s leadership in multiplex proteomic profiling, we are unlocking new opportunities for innovation in discovery and clinical development,” Andrea Jackson, partner at Vizgen and Ultivue investor Northpond Ventures, said in a statement.

Cambridge, Massachusetts-based Ultivue develops assays and reagents for tissue-based biomarker research and discovery including the InSituPlex assays and Starvue platform. It raised $22 million in 2019 and $50 million in a Series D round in 2021.

Vizgen, a Harvard University spinout commercializing MERFISH (multiplex error-resistant fluorescence

in situ hybridization technology) restructured in March following a round of layoffs in October 2023.